| SEC Form 4 | |
|------------|---|
| FORM | 4 |

4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

| OMB | APP | ROV | ΆΙ |
|-----|--------|-----|------|
| OWD | / 11 1 | | / _ |

| OMB Number: | 3235-0287 |
|---------------------|-----------|
| Estimated average b | ourden |
| hours per response: | 0.5 |

| obligations may continue. See Instruction 1(b). | | | |
|--|--|--|--|
|--|--|--|--|

| V | Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10 |
|---|---|
| | 1(c). See Instruction 10. |

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Addr Weinhoff Gr | ess of Reporting Per | rson [*] | 2. Issuer Name and Ticker or Trading Symbol Centessa Pharmaceuticals plc [CNTA] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) | | | | |
|---------------------------------|----------------------|-------------------|--|---|----------------------------------|--------------------------|--|--|
| | <u>cgory wr</u> | | | | Director | 10% Owner | | |
| , | | | 2 Date of Earliest Transaction (Marth/Dou/Mart) | | Officer (give title below) | Other (specify below) | | |
| (Last) (First) (Middle) | | , | 3. Date of Earliest Transaction (Month/Day/Year) 09/25/2024 | | Chief Business | Officer | | |
| C/O CENTESS | SA PHARMACE | UTICALS PLC | 0)/20/20/1 | | | | | |
| 3RD FL., 1 AS | HLEY RD, ALT | RINCHAM | | | | | | |
| | | | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | vidual or Joint/Group Fili | ng (Check Applicable | | |
| (Street) | | | | Line) | Farme file d has One a Da | | | |
| CHESHIRE X0 WA14 2DT | | WA14 2DT | | ~ | Form filed by One Re | | | |
| | | | | | Form filed by More the Person | an One Reporting | | |
| (City) | (State) | (Zip) | | | | | | |

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | Transaction Code (Instr. | | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | | | 5. Amount of Securities Beneficially Owned Following Reported | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | of Indirect Beneficial Ownership |
|---------------------------------|--|---|-----------------------------|---|--|---------------|----------------------------------|---|--|--|
| | | | Code | v | Amount | (A) or (D) | Price | Transaction(s) (Instr. 3 and 4) | (1150.4) | (Instr. 4) |
| Ordinary Shares ⁽¹⁾ | 09/25/2024 | | S ⁽²⁾ | | 16,619 | D | \$ 15.6883 ⁽³⁾ | 206,750 | D | |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| | (e.g., puts, cans, warrants, options, convertible securities) | | | | | | | | | | | | | | |
|---|---|--|---|------------------------------|---|-----|-----|--|--------------------|---|--|--|--|--|--|
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transa Code (8) | | of | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | | Amount of Securities Underlying Derivative Security (Instr. 5) Security (Instr. 3 and 4) | | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
| | | | | Code | v | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | | | |

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 22, 2024.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$15.485 to \$15.875, inclusive. The Reporting Person undertakes to

provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Remarks:

/s/ Gregory M. Weinhoff

09/27/2024

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.